COMMUNIQUÉS West-GlobeNewswire

Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
20/03/2024
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of [...]
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
20/03/2024
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatment Actively adding sites and enrolling pivotal Phase 3 [...]
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
20/03/2024
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its [...]
Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023
20/03/2024
Efforts now aligned toward the completion of its First Quarter Fiscal 2024 Report on Form 10-Q CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a [...]
Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q
20/03/2024
TUSTIN, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (Nasdaq:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today it received a notice (the “ [...]
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
20/03/2024
Five specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families Orchard Assist patient services program to provide individualized support throughout [...]
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
20/03/2024
SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
20/03/2024
LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye [...]
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
20/03/2024
Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the management of exudating wounds MARIETTA, Ga., March 20, 2024 (GLOBE [...]
Evaxion organise la journée de la recherche et développement et dévoile le vaste potentiel de sa plateforme AI-Immunology™
20/03/2024
La plateforme AI-Immunology™ brevetée ouvre la voie d'une nouvelle ère dans le monde de la découverte, de la conception et du développement de vaccins grâce à des technologies avancées d'IA et d'apprentissage [...]
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
20/03/2024
Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024 Aiming for first oncology launch in 2026 and ten indication [...]
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
20/03/2024
Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief [...]
Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology
20/03/2024
Press Release Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology First publication of the data from the Mont Blanc Phase 3 trial in a peer-reviewed [...]
Nicox : Publication de résultats de l’étude de phase 3 Mont Blanc sur le NCX 470 dans le glaucome dans la revue American Journal of Ophthalmology
20/03/2024
Communiqué de presse Nicox : Publication de résultats de l’étude de phase 3 Mont Blanc sur le NCX 470 dans le glaucome dans la revue American Journal of Ophthalmology Première publication de données de l’étude de phase [...]
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
20/03/2024
Total revenues of €153.7 million, including product sales of €144.6 million Product sales surpassed pre-pandemic (2019) sales by 12% and 2022 sales by 26% Excluding COVID-19 vaccine sales, product sales grew by 63% [...]
Valneva publie ses résultats financiers 2023 et fait un point sur son activité et ses perspectives financières
20/03/2024
Chiffre d’affaires total de 153,7 millions d’euros dont 144,6 millions d’euros de ventes de produits Les ventes de produits sont supérieures de 12 % à celles précédant la pandémie (2019) et de 26 % à celles de 2022 En [...]
FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director
20/03/2024
PRESS RELEASE FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director Appointment underscores FundaMental’s ambition to develop medicines for neurodegenerative diseases based on a [...]
BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress
20/03/2024
PRESS RELEASE Preclinical data in a transgenic mouse model shows beneficial effects on various clinical symptoms analogous to those observed in human systemic sclerosis. Findings may further support future clinical [...]
BioSenic présente des données précliniques concluantes sur son médicament ATO pour le contrôle des principaux symptômes au Congrès mondial 2024 sur la sclérose systémique
20/03/2024
COMMUNIQUE DE PRESSE Des données précliniques dans un modèle de souris transgénique montrent des effets bénéfiques sur divers symptômes cliniques analogues à ceux observés dans la sclérose systémique humaine. Les [...]

Pages